OKYO Stock Analysis: Buy, Sell, or Hold?
OKYO - OKYO Pharma Limited Ordinary Shares
$1.40
-0.07 (-4.76%)
âŧ
5d:
-0.71%
30d:
+1.45%
90d:
-14.63%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Jul 17, 2026
0d
Get Alerted When OKYO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: OKYO is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: OKYO is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: OKYO is currently trading at $1.40, which is considered fair relative to its 30-day fair value range of $1.34 to $1.45.
Technical Outlook: Technically, OKYO is in a downtrend. The price is currently testing key support at $1.37. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.8% recently.
Market Sentiment: The stock scores a mixed 49/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $8.33 (+495.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OKYO is in a downtrend. The price is currently testing key support at $1.37. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.8% recently.
Market Sentiment: The stock scores a mixed 49/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $8.33 (+495.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.34 -
$1.45
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (49/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.8%)
- BULLISH: Trading 495.2% below Wall St target ($8.33)
- WARNING: Composite score 50/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.34 -
$1.45
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.37
Resistance Level
$1.65
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.00
Wall Street Target
$8.33
(+495.2%)
Share & Embed Analysis
Last updated: October 26, 2026 3:54 AM ET
Data refreshes hourly during market hours. Next update: 4:54 AM
Data refreshes hourly during market hours. Next update: 4:54 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OKYO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1144 | 52 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 49 HOLD |
|
DNTH
Dianthus Therapeutics InâĻ |
STRONG BUY
17 analysts |
$141 | 52 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 47 HOLD |
|
ELVN
Enliven Therapeutics Inc. |
STRONG BUY
14 analysts |
$74 | 65 BUY |
